As skeletal muscle is one of the most vulnerable tissues to SMN1 insufficiency, revealing muscle-autonomous molecular mechanisms in SMA disease is crucial for developing therapies that prevent the loss of skeletal muscle and that can be combined with the restoration of SMN in motor neurons. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.